Press release
Investors Alert: EMCORE (NASDAQ: EMKR), AGBA Group (NASDAQ: AGBA), Peraso Inc. (NASDAQ: PRSO) and CS Diagnostics (OTC: FZRO) Surge on Game-Changing News
EMCORE Corporation (NASDAQ: EMKR) saw its shares soar today following a major announcement from Mobix Labs (NASDAQ: MOBX). Mobix Labs, a leader in advanced wireless solutions for military and defense, has submitted a proposal to acquire all outstanding shares of EMCORE for $3.80 per share in cash, positioning itself as a key player in the aerospace and defense sectors. This move could provide immediate value to shareholders, making it an attractive opportunity for those looking to capitalize on this offer. Read more. [https://www.businesswire.com/news/home/20240930227038/en/]In parallel, Peraso Inc. (NASDAQ: PRSO) has made significant strides with new strategic purchase orders, including deals with a Kenyan internet provider for its DUNE platform and a Korean contract to supply high-speed internet technology on trains. Additionally, Peraso secured a major military contract, further cementing its leadership in the 60 GHz mmWave technology market. Analysts at Benchmark have issued a "Buy" rating with a $4 price target, projecting strong growth fueled by its global expansion and military contracts. With a projected revenue surge in FY25, Peraso is a company investors should keep on their radar. Read entire report. [https://thestreetreports.com/wp-content/uploads/2024/09/CR_PRSO_09172024.pdf]
AGBA Group Holding Limited (NASDAQ: AGBA) also announced a pivotal moment in its growth trajectory with an amended merger agreement with Triller Corp. AGBA is expanding into high-growth social media and entertainment sectors through Triller's AI-powered platform, unlocking new revenue channels such as pay-per-view and influencer sponsorships. This merger not only increases AGBA's revenue potential but also positions it for significant global growth. For investors looking to capitalize on a diversified, tech-driven company with strong growth prospects, AGBA offers a timely investment opportunity.
CS Diagnostics Group (OTC: FZRO) has surged from its July 2024 low of $0.20 to close at $3.10 on September 27, 2024, after a landmark agreement to sell and transfer its CS Protect-Hydrogel assets, including patents, to CS Diagnostics Corp. The hydrogel, designed to protect healthy tissues during radiation therapy, received a valuation exceeding 960 million, supported by the precedent of a similar product acquired by Boston Scientific for $500 million in 2018. As part of the transaction, CS Diagnostics Corp. issued 110 million shares of common stock, equating to a $500 million payment-making this a stock to watch closely.
With EMCORE Corporation (NASDAQ: EMKR) poised for acquisition, Peraso Inc.'s (NASDAQ: PRSO) global expansion, AGBA Group's (NASDAQ: AGBA) strategic merger with Triller and CS Diagnostics Group (OTC: FZRO) a stock to watch. These companies are positioned for strong growth and value creation. Now is the time for forward-thinking investors to take action and seize the opportunities presented by these market movers.
Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.
Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=investors-alert-emcore-nasdaq-emkr-agba-group-nasdaq-agba-peraso-inc-nasdaq-prso-and-cs-diagnostics-otc-fzro-surge-on-gamechanging-news]
Country: United States
Website: http://www.thestreetreports.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investors Alert: EMCORE (NASDAQ: EMKR), AGBA Group (NASDAQ: AGBA), Peraso Inc. (NASDAQ: PRSO) and CS Diagnostics (OTC: FZRO) Surge on Game-Changing News here
News-ID: 3673175 • Views: …
More Releases from ABNewswire

Chronic Kidney Disease Market Outlook 2034 - Clinical Trials, Market Size, Medic …
Key Chronic Kidney Disease Companies are ProKidney, Reata Pharmaceuticals, Inc., Novo Nordisk A/S, Boehringer Ingelheim, Eli Lilly and Company, KBP Biosciences, Kibow Pharma, Cincor Pharma, AstraZeneca, Allena Pharmaceuticals, DiaMedica Therapeutics Inc., Lexicon Pharmaceuticals, Sanofi, and others.
Chronic Kidney Disease Summary
The Chronic Kidney Disease (CKD) market in the United States was estimated at approximately USD 2,824 million in 2023 and is projected to demonstrate sustained growth throughout the forecast period. The US…

Wet Age-Related Macular Degeneration Market Forecast to 2034: Outlook Therapeuti …
DelveInsight's "Wet AMD - Market Insight 2034" covers the 7MM market with key players like Opthea, Outlook, Kodiak, Regenxbio, and IVERIC bio, highlighting emerging therapies and growing patient demand, while sparking curiosity about which next-generation treatment could redefine Wet AMD care.
In August 2025, Outlook Therapeutics announced a regulatory update that drew significant attention in the Wet Age-Related Macular Degeneration market. The FDA issued a Complete Response Letter (CRL) to the…

BIS Research Empowers Healthcare Industry with Precision-Driven Primary Market R …
BIS Research is redefining healthcare intelligence through Primary Market Research (PMR), offering validated, real-world data on treatment adoption, patient behavior, and technology uptake. Covering 25+ therapeutic areas, BIS supports pharma, diagnostics, and medtech innovators in aligning with trends like AI adoption, precision medicine, and post-COVID digital healthcare, driving sustainable growth worldwide.
BIS Research, a leading global B2B market intelligence and advisory firm, today announced the expansion of its Primary Market Research…

IBN Technologies' AP AR Automation Drives Financial Growth for U.S. Real Estate …
AP AR automation is reshaping real estate financial management across the U.S. IBN Technologies' end-to-end solutions automate invoice capture, validation, payment processing, and collections while delivering real-time reporting. With benefits such as 30% faster cash flow, 25% more on-time payments, and seamless ERP integration, firms gain stronger financial control and long-term resilience in an evolving market.
Miami, Florida, 03 Sep 2025 The adoption of digital solutions is accelerating in the U.S.…
More Releases for NASDAQ:
Peraso (NASDAQ: PRSO) Pushes Back on Mobix Labs (NASDAQ: MOBX) Takeover Bid, Val …
Peraso Inc. (NASDAQ: PRSO), a leading innovator in mmWave wireless solutions, has officially acknowledged receipt of an unsolicited, non-binding acquisition proposal from Mobix Labs, Inc. (NASDAQ: MOBX). The offer proposes a stock-for-stock exchange that values Peraso at approximately $1.20 per share, representing a 20% premium over its 30-day average closing price. However, Peraso is contesting several key points made in Mobix's June 26 press release.
Financials Mischaracterized, Says Peraso
Peraso rebuffed Mobix's…
ZenaTech's (Nasdaq: ZENA) Nasdaq Listing: A Launchpad for Growth and Innovation
On October 1, ZenaTech (Nasdaq: ZENA) made its debut on the Nasdaq, a pivotal milestone for the company specializing in AI-driven drone solutions and enterprise SaaS (software-as-a-service) applications. As businesses increasingly seek innovative ways to streamline operations and boost productivity, ZenaTech stands ready to meet these demands with its advanced AI drone solutions and comprehensive software applications. Under the leadership of CEO Dr. Shaun Passley, ZenaTech aims to leverage its…
Market Movers to Watch: Black Diamond (Nasdaq: BDTX), Peraso Inc. (NASDAQ: PRSO) …
Pre-market trading is heating up as Black Diamond Therapeutics, Inc. (Nasdaq: BDTX) surges on positive Phase 2 data for its cancer treatment BDTX-1535. Peraso Inc. (NASDAQ: PRSO) continues its expansion into the Asian markets and a major military contract. Kaival Brands (NASDAQ: KAVL) saw its stock surge in early trading today on merger announcement. Other stocks to watch include Banzai International Inc. (NASDAQ: BNZI), which saw a 97.51% rally after…
Lawsuit filed for Investors who lost money with Alphabet Inc. (NASDAQ: GOOG, NAS …
An investor, who purchased shares of Alphabet Inc. (NASDAQ: GOOG, NASDAQ: GOOGL), filed a lawsuit over alleged violations of Federal Securities Laws by Alphabet Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Alphabet Inc. (NASDAQ: GOOG, NASDAQ: GOOGL), have certain options and for certain investors are short and strict deadlines running. Deadline: May 15, 2023. NASDAQ: GOOG, NASDAQ: GOOGL investors should contact the Shareholders…
Investigation announced for Investors in NASDAQ: MTTR over possible Wrongdoing a …
An investigation was announced for investors in shares of Matterport, Inc. (NASDAQ: MTTR) was announced over potential breaches of fiduciary duties by certain officers and directors at Matterport, Inc.
Investors who purchased shares of Matterport, Inc. (NASDAQ: MTTR) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Matterport, Inc. directors breached their fiduciary duties and…
Investigation announced for Investors in shares of Alphabet Inc. (NASDAQ: GOOG, …
An investigation was announced on behalf of investors of Alphabet Inc. (NASDAQ: GOOG, NASDAQ: GOOGL) shares over potential securities laws violations by Alphabet Inc. in connection with certain financial statements.
Investors who purchased shares of Alphabet Inc. (NASDAQ: GOOG, NASDAQ: GOOGL), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers…